Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes

被引:112
作者
Rawden, HC
Kokwaro, GO
Ward, SA
Edwards, G [1 ]
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Ashton St Med Sch, Liverpool L69 3GE, Merseyside, England
[2] Univ Nairobi, Dept Pharm & Pharm Practice, Nairobi, Kenya
[3] Univ Liverpool, Liverpool Sch Trop Med, Div Parasite & Vector Biol, Liverpool L3 5QA, Merseyside, England
关键词
albendazole; anthelmintic; FMO; metabolism; P450;
D O I
10.1046/j.1365-2125.2000.00170.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Albendazole (ABZ; methyl 5-propylthio-1H-benzimidazol-2-yl carbamate) is a broad spectrum anthelmintic whose activity resides both in the parent compound and its sulphoxide metabolite (ABS). There are numerous reports of ABZ metabolism in animals but relatively few in humans. We have investigated the sulphoxidation of ABZ in human liver microsomes and recombinant systems. Methods The specific enzymes involved in the sulphoxidation of ABZ were determined by a combination of approaches; inhibition with an antiserum directed against cytochrome P450 reductase, the effect of selective chemical inhibitors on ABZ sulphoxidation in human liver microsomes, the capability of expressed CYP and FMO to mediate the formation of ABS, regression analysis of the rate of metabolism of ABZ to ABS in human liver microsomes against selective P450 substrates and regression analysis of the rate of ABS sulphoxidation against CYP expression measured by Western blotting. Results Comparison of V-max values obtained following heat inactivation (3 min at 45 degrees C) of flavin monoxygenases (FMO), chemical inhibition of FMO with methimazole and addition of an antiserum directed against cytochrome P450 reductase indicate that FMO and CYP contribute approximate to 30% and 70%, respectively, to ABS production in vitro. Comparison of CLint values suggests CYP is a major contributor in vivo. A significant reduction in ABZ sulphoxidation (n = 3) was seen with ketoconazole (CYP3 A4; 32-37%), ritonavir (CYP3 A4: 34-42%), methimazole (FMO: 28-49%) and thioacetamide (FMO; 32-35%). Additive inhibition with ketoconazole and methimazole was 69 +/- 8% (n = 3). ABS production in heat - treated microsomes (3 min at 45 degrees C) correlated significantly with testosterone 6 beta-hydroxylation (CYP3A4; P < 0.05) and band intensities on Western blots probed with an antibody selective for 3A4 (P < 0.05). Recombinant human CYP3 A4, CYP1A2 and FMO3 produced ABS in greater quantities than control microsomes, with those expressing CYP3A4 producing threefold more ABS than those expressing CYP1A2. Kinetic studies showed the K-m values obtained with both CYP3A4 and FMO3 were similar. Conclusions We conclude that the production of ABS in human liver is mediated via both FMO and CYP, principally CYP3A4, with the CYP component being the major contributor.
引用
收藏
页码:313 / 322
页数:10
相关论文
共 31 条
[1]  
AMRI HS, 1988, J PHARMACOL EXP THER, V246, P758
[2]  
[Anonymous], ENZYMATIC BASIS DETO
[3]   KETOCONAZOLE AND SULFAPHENAZOLE AS THE RESPECTIVE SELECTIVE INHIBITORS OF P4503A AND 2C9 [J].
BALDWIN, SJ ;
BLOOMER, JC ;
SMITH, GJ ;
AYRTON, AD ;
CLARKE, SE ;
CHENERY, RJ .
XENOBIOTICA, 1995, 25 (03) :261-270
[4]   Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir [J].
Eagling, VA ;
Back, DJ ;
Barry, MG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (02) :190-194
[5]  
Gentile DM, 1996, J PHARMACOL EXP THER, V277, P105
[6]   THE METABOLISM OF BENZIMIDAZOLE ANTHELMINTICS [J].
GOTTSCHALL, DW ;
THEODORIDES, VJ ;
WANG, R .
PARASITOLOGY TODAY, 1990, 6 (04) :115-&
[7]  
Griffin JP, 1997, MANUAL ADVERSE DRUG
[8]   A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes [J].
Grothusen, A ;
Hardt, J ;
Brautigam, L ;
Lang, D ;
Bocker, R .
ARCHIVES OF TOXICOLOGY, 1996, 71 (1-2) :64-71
[9]  
Guo ZY, 1997, DRUG METAB DISPOS, V25, P390
[10]   SELECTIVE INHIBITORS OF CYTOCHROMES P450 [J].
HALPERT, JR ;
GUENGERICH, FP ;
BEND, JR ;
CORREIA, MA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1994, 125 (02) :163-175